

DAFTAR PUSTAKA

- Aapro, M., Caprariu, Z., Chilingirov, P., Chrápavá, M., Curca, R. O., Gales, L., Grigorescu, A. C., Huszno, J., Karlínová, B., Kellnerová, R., Malejčíková, M., Marinca, M., Petru, E., Płużanski, A., Pokorná, P., Pribulova, Z., Rubach, M., Steger, G. G., Tesařová, P., ... Walaszowska-Czyz, A. (2022). Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emetis registry in oncology (NERO). *European Journal of Cancer*, 166, 126–133. <https://doi.org/10.1016/j.ejca.2022.01.028>
- Aksu, G., Dolaşık, I., Ensaroğlu, F., Şener, S. Y., Aydın, F. H., Temiz, S., Canoğlu, D., & Uygun, K. (2013). Evaluation of the efficacy of aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life with functional living index emesis. *Balkan Medical Journal*, 30(1), 64–67. <https://doi.org/10.5152/balkanmedj.2012.087>
- Al-Bairmany, Y. S. R., Hadi, N. K., & Nazar, A. K. (2022). The efficacy of single dose palonosetron in highly emetogenic chemotherapy protocols compared to oral aprepitant and ondansetron. *Journal of Pharmacovigilance and Drug Research*. <https://doi.org/https://doi.org/10.53411/jpadr.2022.3.3.06>
- All, D. et. (2008). *Pharmacotherapy a Pathophysiologic Approach Seventh Edition* (Seventh, Vol. 3, Issue 1). McGraw Hill. <https://medium.com/@arifwicaksanaa/pengertian-use-case-a7e576e1b6bf>
- American Cancer Society. (2020). Ovarian cancer causes, risk factors and prevention. *Cancer.Org*, 5. www.cancer.org/cancer/acs-medical-content-and-news-staff.html
- American Cancer Society. (2023a). *2023 Cancer Facts and Figures* (Issue 77, pp. 10–12).
- American Cancer Society. (2023b). Ovarian Cancer Early Detection , Diagnosis , and Staging. *American Cancer Society, cancer.org*, 1–24. <https://www.cancer.org/content/dam/CRC/PDF/Public/8661.00.pdf>
- Ariyanti, N. F. (2007). *Evaluasi penggunaan antiemetik pada kemoterapi kanker ovarium di RSUP Dr. sardjito Yogyakarta*.
- Arulkumaran S, Ledger W, Denny L, D. S. (2020). Oxford Textbook of Obstetrics and Gynaecology. *Oxford Textbook of Obstetrics and Gynaecology*. <https://doi.org/10.1093/med/9780198766360.001.0001>
- Awosika, A. O., Farrar, M. C., & Jacobs, T. F. (2024). *Paclitaxel*.
- Ballatori, E., & Roila, F. (2003). Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. *Health and Quality of Life Outcomes*, 1,

1–11. <https://doi.org/10.1186/1477-7525-1-46>

- Barbara et al. (2012). *Williams Gynecology Second Edition Study Guide.pdf* (second edi). McGraw Hill.
- Berek, J. S., Friedlander, M. L., & Hacker, N. F. (2017). Epithelial ovarian, fallopian tube, and peritoneal cancer. *Berek and Hacker's Gynecologic Oncology: Sixth Edition*, 464–529. <https://doi.org/10.1002/9781119000822.hfcm105.pub2>
- Bookshelf, N., Library, N., & Institutes, N. (2020). *Carboplatin. Md.* <https://www.ncbi.nlm.nih.gov/books/NBK548565/>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. <https://doi.org/10.3322/caac.21492>
- Britain, R. P. S. O. G. (2002). *British National Formulary* (44th ed.). British Medical Association.
- Caan, B. J., & Thomson, C. A. (2007). Breast and ovarian cancer. *Optimizing Women's Health through Nutrition*, 229–263. <https://doi.org/10.1369/0022155411428469>
- Calabreasi, C. B. A. (2017). Kemoterapi Penyakit Neoplastik. In *Goodman & Gilman. Dasar Farmakologi Terapi*. (pp. 1353–1431).
- Cancer Council Australia. (2022). Understanding Ovarian Cancer. *Cancer Council*, 1–76.
- Celio, L. (2022). *Emetogenicity of chemotherapy regimens and recommended prophylaxis: a review of MASCC/ESMO guidelines. June 2022*, 60–67.
- Chaudhary, N. K., John, R. R., Boddu, D., Mahasampath, G., Nesadeepam, N., & Mathew, L. G. (2019). Palonosetron is a Better Choice Compared with Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results from a Randomized Control Trial. *Journal of Pediatric Hematology/Oncology*, 41(4), 294–297. <https://doi.org/10.1097/MPH.0000000000001357>
- Chhikara, B. S., & Parang, K. (2023). Global Cancer Statistics 2022: the trends projection analysis. *Chemical Biology Letters*, 10(1).
- Coleman, R. L., Hennessy, B. T., Coleman, R. L., & Markman, M. (2023). Ovarian cancer Ovarian cancer. *Critical Reviews in Oncology/Hematology*, June, 433–440. <https://www.sciencedirect.com/science/article/abs/pii/S1040842806000643?via%3Dihub>
- De Mulder, P. H. M., Seynaeve, C., Vermorcken, J. B., Van Liessum, P. A., Mols-

- Jevdevic, S., Allman, E. L., Beranek, P., & Verweij, J. (1990). Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting a multicenter, randomized, double-blind, crossover study. *Annals of Internal Medicine*, 113(11), 834–840.
- Desai, A. (2014). Epithelial ovarian cancer: An overview. *World Journal of Translational Medicine*, 3(1), 1. <https://doi.org/10.5528/wjtm.v3.i1.1>
- Dhitayoni, I., & Budiana, I. (2017). Profil Pasien Kanker Ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar – Bali Periode Juli 2013 – Juni 2014. *E-Jurnal Medika*, 6(3), 1–9.
- Dipiro et al. (2005). Nausea and Vomiting. In *Pharmacotherapy : A Pathophysiologic Approach 6th edition* (6th ed., pp. 665–676). The McGraw-Hill Companies.
- Dipiro et al. (2021). Pharmacotherapy Handbook Eleventh Edition. In *The American Journal of Digestive Diseases* (11th ed.). McGraw Hill. <https://doi.org/10.1007/BF02231363>
- Distinarista, W. F. G. . R. (2024). *Pengaruh Aromaterapi Lavender dan relaksasi Otot Progresif Terhadap Mual dan Muntah Pada Pasien kanker Ovarium Yang menjalankan Kemoterapi di RSUP Dr. Kariadi Semarang*. 105–114.
- Dorland. (2002). *Kamus Kedokteran* (29th ed.). Penerbit Buku Kedokteran EGC.
- Doubeni, C. A., Doubeni, A. R. B., & Myers, A. E. (2016). Diagnosis and management of ovarian cancer. *American Family Physician*, 93(11), 937–944.
- Drugbank Online. (2024). *Carboplatin*. <https://go.drugbank.com/drugs/DB00958>
- DrugBank Online. (n.d.). *Docetaxel* Summary. <https://go.drugbank.com/drugs/DB01248>
- DrugBank Online. (2024). *Paclitaxel* Summary. <https://go.drugbank.com/drugs/DB01229>
- Elvina, R., Musyarofah, R., & Putri, R. A. (2017). Evaluasi Penggunaan Obat Antimuntah Pada Pasien Anak Penderita Kanker Di Rumah Sakit Kanker Dharmais Jakarta Periode Juni-Juli 2016. *Media Farmasi: Jurnal Ilmu Farmasi*, 14(1), 91. <https://doi.org/10.12928/mf.v14i1.9829>
- Ettinger et al. (2023). *NCCN Clinical Practice Guideline in Oncology Antiemesis* (Version 2.). Natinonal Comprehensive Cancer Network Inc. All Rights Reserved.
- Farha, N. G., & Kasi, A. (2024). *Docetaxel*.
- Farid Aziz. (2006). *Buku Acuan Nasional Onkologi Ginekologi*. Yayasan Bina Pustaka Sarwono Prawirohardjo.
- Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., &

- Bray, F. (2021). Cancer statistics for the year 2020: An overview. *International Journal of Cancer*, 149(4), 778–789. <https://doi.org/10.1002/ijc.33588>
- Fidinillah, M., & Karuniawati, H. (2021). Evaluasi Penggunaan Obat Antiemetika Pada Pasien Kanker Serviks Di Rsud Dr. Moewardi Surakarta Tahun 2018. *Urecol*, 243–248.
- Gala, D., Wright, H. H., Zigori, B., Marshall, S., & Crichton, M. (2022). Dietary strategies for chemotherapy-induced nausea and vomiting: A systematic review. *Clinical Nutrition*, 41(10), 2147–2155. <https://doi.org/10.1016/j.clnu.2022.08.003>
- Globocan. (2019). Indonesia Source GLOBOCAN 2018. *International Agency for Research on Cancer*, 256, 1–2. <http://gco.iarc.fr/>
- Grunberg, S. M., & Koeller, J. M. (2003). Palonosetron: A unique 5-HT₃ -receptor antagonist for the prevention of chemotherapy-induced emesis. *Expert Opinion on Pharmacotherapy*, 4(12), 2297–2303. <https://doi.org/10.1517/14656566.4.12.2297>
- Gupta, K., Walton, R., & Kataria, S. P. (2021). Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. In *Cancer Treatment and Research Communications* (Vol. 26). Elsevier Ltd. <https://doi.org/10.1016/j.ctarc.2020.100278>
- Harahap SD. (2013). *Efektivitas Penatalaksanaan Mual dan Munath Pada Pasien Kanker ovarium Yang mendapat Kemoterapi yang Dinilai dengan Functional Living Indeks Emesis (FLIE)*.
- Hesketh, P. J. (1999). Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice. *The Oncologist*, 4(3), 191–196. <https://doi.org/10.1634/theoncologist.4-3-191>
- Hilarius, D. L., Kloeg, P. H., Van Der Wall, E., Van Den Heuvel, J. J. G., Gundy, C. M., & Aaronson, N. K. (2012). Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study. *Supportive Care in Cancer*, 20(1), 107–117. <https://doi.org/10.1007/s00520-010-1073-9>
- HOGI. (2018). *Pedoman Nasional Pelayanan Kedokteran Kanker Ovarium*.
- Hsu, Y., Sood, A. K., & Sorosky, J. I. (2004). Docetaxel Versus Paclitaxel for Adjuvant Treatment of Ovarian Cancer: Case-Control Analysis of Toxicity. *American Journal of Clinical Oncology: Cancer Clinical Trials*, 27(1), 14–18. <https://doi.org/10.1097/01.coc.0000045849.95834.6B>
- Joerger, M. (2012). Prevention and handling of acute allergic and infusion reactions in oncology. *Annals of Oncology*, 23(SUPPL. 10), x313–x319. <https://doi.org/10.1093/annonc/mds314>
- Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012). Therapeutic strategies in

- epithelial ovarian cancer. *Journal of Experimental and Clinical Cancer Research*, 31(1), 1–8. <https://doi.org/10.1186/1756-9966-31-1422330607>
- Kris, M. G., Gralla, R. J., Clark, R. A., Tyson, L. B., O'Connell, J. P., Wertheim, M. S., & Kelsen, D. P. (1985). Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. *Journal of Clinical Oncology*, 3(10), 1379–1384. <https://doi.org/10.1200/JCO.1985.3.10.1379>
- Kumar A. (2013). Antiemetics: A review. *International Journal of Pharmaceutical Sciences and Research*, 4(1), 113–123. <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L368388152%5Cnhttp://www.ijpsr.com/V4I1/12> Vol. 4, Issue 1, January 2013, IJPSR, 794, Paper 12.pdf%5Cnhttp://elvis.ubvu.vu.nl:9003/vulink?sid=EMBASE&issn=23205148&id=doi:&atitle=A
- Lachaine, J., Laurier, C., Langleben, A., & Vaillant, L. (1999). Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. *Critical Reviews in Oncology/Hematology*, 32(2), 105–112. [https://doi.org/10.1016/S1040-8428\(99\)00025-6](https://doi.org/10.1016/S1040-8428(99)00025-6)
- Lindley, C. M., Hirsch, J. D., O'Neill, C. V., Transau, M. C., Gilbert, C. S., & Osterhaus, J. T. (1992). Quality of life consequences of chemotherapy-induced emesis. *Quality of Life Research*, 1(5), 331–340. <https://doi.org/10.1007/BF00434947>
- Mahyenda, N., Muhammad, S., & Asri, A. (2023). Hubungan Skor RMI Dengan Stadium Kanker Ovarium Tipe Epitel Di RSUP Dr. M. Djamil Padang. *Jurnal Ilmu Kesehatan Indonesia*, 3(3), 210–216. <https://doi.org/10.25077/jikesi.v3i3.668>
- Martin, A. R., Carides, A. D., Pearson, J. D., Horgan, K., Elmer, M., Schmidt, C., Cai, B., Chawla, S. P., & Grunberg, S. M. (2003). Functional relevance of antiemetic control: Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. *European Journal of Cancer*, 39(10), 1395–1401. [https://doi.org/10.1016/S0959-8049\(03\)00299-5](https://doi.org/10.1016/S0959-8049(03)00299-5)
- Martin, A. R., Pearson, J. D., Cai, B., Elmer, M., Horgan, K., & Lindley, C. (2003). Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: A modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. *Supportive Care in Cancer*, 11(8), 522–527. <https://doi.org/10.1007/s00520-003-0482-4>
- Micha, J. P., Rettenmaier, M. A., Brown, J. V., Mendivil, A., Abaid, L. N., Lopez, K. L., & Goldstein, B. H. (2016). A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea

- and Vomiting in Patients Treated for Gynecologic Cancer. *International Journal of Gynecological Cancer*, 26(2), 389–393. <https://doi.org/10.1097/IGC.0000000000000593>
- Michaud, L. B., Valero, V., & Hortobagyi, G. (2000). Risks and benefits of taxanes in breast and ovarian cancer. *Drug Safety*, 23(5), 401–428. <https://doi.org/10.2165/00002018-200023050-00005>
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: Epidemiology and risk factors. *International Journal of Women's Health*, 11, 287–299. <https://doi.org/10.2147/IJWH.S197604>
- Mosa, A. S. M., Mosharraf Hossain, A., Lavoie, B. J., & Yoo, I. (2020). Patient-related risk factors for Chemotherapy-Induced Nausea and Vomiting: A systematic review. *Frontiers in Pharmacology*, 11(April), 1–15. <https://doi.org/10.3389/fphar.2020.00329>
- National Cancer Institute. (2023). *PDQ Supportive and Palliative Care Editorial Board. Nausea and Vomiting Related to Cancer Treatment*. <https://www.ncbi.nlm.nih.gov/books/NBK66056/>
- National Comprehensive Cancer Network. (2022). *Guidelines For Patients Nausea and Vomiting* (pp. 6–37).
- Navari, R. M. (2015). Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. *BioMed Research International*, 2015, 6–11. <https://doi.org/10.1155/2015/595894>
- Navari, R. M., & Aapro, M. (2016). Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. *New England Journal of Medicine*, 374(14), 1356–1367. <https://doi.org/10.1056/nejmra1515442>
- Parathoduvil, A. A., Sisupalan, A., & Rema, P. L. (2017). Comparison of antiemetic effectiveness of palonosetron versus ondansetron in patients on cancer chemotherapy: A prospective observational study in south Indians. *Journal of Clinical and Diagnostic Research*, 11(5), FC10–FC14. <https://doi.org/10.7860/JCDR/2017/25129.9818>
- Pasricha. (2021). Obat Prokinetik dan Obat yang Digunakan dalam Sindron Iritasi Usus. In *Goodman and Gilman Edisi 10. Dasar Farmakoterapi*. (Vol. 2, pp. 993 – 1008).
- Purdie, D. M., Bain, C. J., Siskind, V., Webb, P. M., & Green, A. C. (2003). Ovulation and risk of epithelial ovarian cancer. *International Journal of Cancer*, 104(2), 228–232. <https://doi.org/10.1002/ijc.10927>
- Rao, K. V., & Faso, A. (2012). Chemotherapy-induced nausea and vomiting: Optimizing prevention and management. *American Health and Drug Benefits*, 5(4).

- Rapoport, B. L. (2017). Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. *Frontiers in Pharmacology*, 8(JAN), 1–10. <https://doi.org/10.3389/fphar.2017.00019>
- Rojas, C., Li, Y., Zhang, J., Stathis, M., Alt, J., Thomas, A. G., Cantoreggi, S., Sebastiani, S., Pietra, C., & Slusher, B. S. (2010). The antiemetic 5-HT₃ receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. *Journal of Pharmacology and Experimental Therapeutics*, 335(2), 362–368. <https://doi.org/10.1124/jpet.110.166181>
- Shih, V., Wan, H. S., & Chan, A. (2009). Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. *Annals of Pharmacotherapy*, 43(3), 444–452. <https://doi.org/10.1345/aph.1L437>
- Shinta, N., & Surarso, B. (2016). Terapi Mual dan Muntah Pasca Kemoterapi. *Jurnal THT-KL*, 9(2), 74–82. <http://journal.unair.ac.id/download-fullpapers-thtklac6b53d6eefull.pdf>
- Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. *CA: A Cancer Journal for Clinicians*, 72(1), 7–33. <https://doi.org/10.3322/caac.21708>
- Society, A. C. (2018). Special Section : Ovarian Cancer. *Cancers Facts and Figures*, 45(2), 28–43.
- Sukardja IDG. (2000). *Onkologi Klinik* (2nd ed.). Pusat Penerbitan dan Percetakan UNAIR.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Sutadarma, I. W. G. (2022). Direktorat Jenderal Pelayanan Kesehatan. In *Kementerian Kesehatan RI*. https://yankes.kemkes.go.id/view_artikel/1222/gula-si-manis-yang-menyebabkan-ketergantungan
- Sweetman, S. (2009). *Martindale : The Drug Complete Reference* (36th ed.). London Pharmaceutical Press.
- Syamel, M., & Fajriman, F. (2023). Hubungan Nilai PCI Intraoperatif dengan Resektabilitas Kanker Ovarium di RSUP Dr. M. Djamil Padang. *Indonesian Journal of Obstetrics & Gynecology Science*, 6(3), 365–373. <https://doi.org/10.24198/obgynia.v6.n3.532>
- Takatori, E., Shoji, T., Miura, Y., Nagao, M., Takada, A., Nagasawa, T., Omi, H., Kagabu, M., Honda, T., & Sugiyama, T. (2015). A phase II clinical trial of

- palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. *Molecular and Clinical Oncology*, 3(2), 281–286. <https://doi.org/10.3892/mco.2015.484>
- Umar, R. M. (2018). Drug-drug interactions between antiemetics used in cancer patients. In *Journal of Oncological Sciences* (Vol. 4, Issue 3, pp. 142–146). <https://doi.org/10.1016/j.jons.2018.07.003>
- Warr, D. G. (2008). Chemotherapy-and cancer-related nausea and vomiting. *Current Oncology*, 15(S1), S4–S9. <https://doi.org/10.3747/co.2008.171>
- Webb, P. M., & Jordan, S. J. (2017). Epidemiology of epithelial ovarian cancer. *Best Practice and Research: Clinical Obstetrics and Gynaecology*, 41, 3–14. <https://doi.org/10.1016/j.bpobgyn.2016.08.006>
- Wood, J. M., Chapman, K., & Eilers, J. (2011). Tools for assessing nausea, vomiting, and retching: A literature review. *Cancer Nursing*, 34(1). <https://doi.org/10.1097/NCC.0b013e3181e2cd79>
- Wulandari, M. R. S. (2017). Komparasi Kualitas Hidup Wanita Penderita Kanker Serviks Dan Kanker Ovarium Berdasarkan Siklus Kemoterapi. *Seminar Dan Workshop Nasional 2017*, 1(1), 199–205.
- Zhong, W., Shahbaz, O., Teskey, G., Beaver, A., Kachour, N., Venketaraman, V., & Darmani, N. A. (2021). Mechanisms of nausea and vomiting: Current knowledge and recent advances in intracellular emetic signaling systems. *International Journal of Molecular Sciences*, 22(11). <https://doi.org/10.3390/ijms22115797>

